Risk of Thromboembolic Events Following COVID-19 Diagnosis Without HospitalizationArticle Published on 2022-12-232023-07-11 Journal: Journal of the American Board of Family Medicine : JABFM [Category] COVID19(2023년), [키워드] Anticoagulants COVID-19 incidence Retrospective studies SARS-CoV-2 Urban health venous thromboembolism. [DOI] 10.3122/jabfm.2022.220180R2 PMC 바로가기
Drugs for COVID-19: An UpdateReview Published on 2022-12-052023-07-11 Journal: Molecules [Category] COVID19(2023년), [키워드] Antibiotics Anticoagulants antivirals COVID-19 immunomodulators interleukin inhibitors. JAKs inhibitors NSAIDS SARS-CoV-2 [DOI] 10.3390/molecules27238562 PMC 바로가기 [Article Type] Review
A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case reportCase Reports Published on 2022-12-012023-07-08 Journal: Hematology (Amsterdam, Netherlands) [Category] COVID19(2023년), [키워드] Anticoagulants bivalirudin cardiac ventricles COVID-19 heparin percutaneous cardiovascular intervention thrombocytopenia thrombosis. [DOI] 10.1080/16078454.2022.2043572 PMC 바로가기 [Article Type] Case Reports
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACTRandomized Controlled Trial Published on 2022-11-012023-06-20 Journal: Circulation [Category] Fulltext, MERS, [키워드] Anticoagulants clopidogrel COVID-19 hemorrhage Platelet aggregation inhibitors thrombosis. [DOI] 10.1161/CIRCULATIONAHA.122.061533 PMC 바로가기 [Article Type] Randomized Controlled Trial
Thromboprophylaxis with standard- vs. flexible-dose heparin for hospitalized COVID-19 patients: a target trial emulationResearch article Published on 2022-11-012022-10-05 Journal: Journal of clinical epidemiology [Category] 임상, [키워드] 28-day mortality 95% confidence interval Anticoagulants anticoagulation baseline bleeding Coagulopathy COVID-19 COVID-19 diagnosis COVID-19 drug treatment dose eligible Epidemiological methods estimate hazard ratio hospitalized COVID-19 hospitalized COVID-19 patient hospitalized COVID-19 patients intensity intermediate dose laboratory abnormality LMWH Low–molecular weight heparin Major Mortality objective Observational data Patient Result risk setting Spain Standard dose survival target Target trial emulation Thromboprophylaxis thrombosis thrombotic risk Trial [DOI] 10.1016/j.jclinepi.2022.08.006 [Article Type] Research article
Antithrombin as Therapeutic Intervention against Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation: Lessons Learned from COVID-19-Associated CoagulopathyArticle Published on 2022-10-182022-11-15 Journal: International Journal of Molecular Sciences [Category] 바이오마커, [키워드] activity Anticoagulant Anticoagulants Antithrombin benefit Biomarker Coagulopathies Coagulopathy Combination contributed COVID-19 deficiency differential diagnosis Disseminated intravascular coagulation Establishing Evidence heterogeneous population Intervention lesson Pathogenesis recent Research Scoring scoring system Sepsis sepsis patient sepsis. significantly specific treatment Treatment [DOI] 10.3390/ijms232012474 PMC 바로가기
Anticoagulants as Potential SARS-CoV-2 Mpro Inhibitors for COVID-19 Patients: In Vitro, Molecular Docking, Molecular Dynamics, DFT, and SAR StudiesArticle Published on 2022-10-132022-11-15 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 치료제, [키워드] addition Anticoagulant Anticoagulants carried Compound compounds conducted COVID-19 cytotoxicity demonstrated drug Dynamics eligible enzyme highest highest binding affinity Idraparinux in silico in silico approaches in vitro in vitro. inhibitory inhibitory activity inhibitory concentration intrinsic investigated M pro molecular molecular docking MPro MTT performed Potential protease reference standard SAR SARS-CoV-2 SARS-CoV-2 Mpro screened sodium the SARS-CoV-2 thermodynamic [DOI] 10.3390/ijms232012235 PMC 바로가기
The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID studyObservational Study Published on 2022-10-012022-10-05 Journal: Journal of cardiology [Category] COVID19(2023년), SARS, 임상, [키워드] Anticoagulant Anticoagulants anticoagulation Asian bleeding Computed tomography coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection diagnosed with COVID-19 died disease dose enrolled hospital Hospitalization hospitalized patient incidence Japan Major management Mild Moderate COVID-19 multicenter cohort study occurred Patient patients with COVID-19 pharmacological Pneumonia polymerase chain positive proportion Respiratory failure retrospective severe COVID-19 severity the patient therapy Thromboprophylaxis thrombosis thrombosis. unmet need Venous Thromboembolism with COVID-19 [DOI] 10.1016/j.jjcc.2022.03.015 PMC 바로가기 [Article Type] Observational Study
Thrombosis risk assessment in patients with congenital thrombophilia during COVID – 19 infectionResearch article Published on 2022-10-012022-10-05 Journal: Thrombosis research [Category] 변종, 유전자 메커니즘, 진단, [키워드] absence ACAnticoagulants addition adjusted age Anticoagulant Anticoagulants Antithrombin Antithrombotic association ATAntithrombin BMIbody mass index body mass index case-control study changes in clinical picture Comorbidities Comorbidity comparable Computed tomography Confirmed COVID-19 infection contribute Corona Virus Disease COVID COVID-19 COVID-19 infection COVID-19 patient COVID-19 patients COVIDCorona Virus Disease Critical CTComputed Tomography D-dimer D-dimer level Deep venous thrombosis Diagnosis Direct oral anticoagulant disease DOACDirect Oral Anticoagulant DVTDeep Venous Thrombosis dysfunction evaluate Factor V Leiden factor VIII FEUFibrinogen Equivalent Fibrinogen Equivalent FII G20210AProthrombin mutation Final FV LeidenFactor V Leiden FVIII FVIIIFactor VIII genetic defect HBSHeparin Binding Site Heparin Binding Site individual Infection LMWHlow molecular weight heparin low molecular weight heparin Mild Odds ratio OROdds Ratio outcome parameter Patient patient group PCR/RFLPpolymerase chain reaction/restriction fragment length polymorphism PEPulmonary Embolism polymerase chain reaction/restriction fragment length polymorphism Prophylaxis Prothrombin mutation Pulmonary embolism receive Result risk risk of COVID-19 serious complication severe COVID-19 significantly significantly increased symptomatic thrombosis thrombotic thrombotic complication thrombotic event Thrombotic events Treatment Unusual Thrombosis UTUnusual Thrombosis Venous Thromboembolism vitamin K antagonist VKAVitamin K antagonist VTEVenous Thromboembolism was performed [DOI] 10.1016/j.thromres.2022.08.020 [Article Type] Research article
Management of Cerebral Venous Thrombosis Due to Adenoviral COVID-19 VaccinationArticle Published on 2022-10-012022-11-15 Journal: Annals of neurology [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI 95% confidence interval adenovirus-based adjusted adjusted odds ratio administration adverse effect analyzed ANN Anticoagulant Anticoagulants association autoimmune pathogenesis avoidance caused cerebral country COVID-19 diagnosed evaluate had no heparin hospital immune immunomodulation International Intravenous immunoglobulin lower mortality Mortality Patient Platelet recommendation reducing mortality SARS-CoV-2 SARS-CoV-2 vaccination significantly statistically significant the patient thrombotic treated Treatment used data Vaccines Venous thrombosis [DOI] 10.1002/ana.26431 PMC 바로가기